graph EGM comparisons
pembrolizumab alonetitleplacebotitleStandard of Care (SoC)titleKEYNOTE-522, 2020 NCT03036488 es-BC - TNBC - NA - all population 784/390KEYNOTE-119 (all population), 2019 NCT02555657 mBC - TNBC - L2 - all population 312/310KEYNOTE-119 (PDL1 CPS>1), 2019 NCT02555657 mBC - TNBC - L2 - PDL1 positive 203/202KEYNOTE-119 (PDL1 CPS>10), 2019 NCT02555657 mBC - TNBC - L2 - PDL1 positive 96/98

Pathology:  es-BC - TNBC - NA - all population;   mBC - TNBC - L2 - all population;   mBC - TNBC - L2 - PDL1 positive; 

es-BC - TNBC - NA - all populationmBC - TNBC - L2 - all populationmBC - TNBC - L2 - PDL1 positive
KEYNOTE-522, 2020KEYNOTE-119 (all population), 2019KEYNOTE-119 (PDL1 CPS>1), 2019KEYNOTE-119 (PDL1 CPS>10), 2019
pembrolizumab alone4T1T1T1T1
placebo0T0
Standard of Care (SoC)0T0T0T0